Vascodagama Online Journal

The Hunter Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Hunter Syndrome Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hunter Syndrome Market.

Some of the key takeaways from the Hunter Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Hunter Syndrome treatment therapies with a considerable amount of success over the years. 
• Hunter Syndrome companies working in the treatment market are Capsida Biotherapeutics, JCR Pharmaceuticals, Takeda, Green Cross Corporation/GC Pharma, Denali Therapeutics, Regenxbio, Sangamo Therapeutics, AVROBIO, and others, are developing therapies for the Hunter Syndrome treatment 

• Emerging Hunter Syndrome therapies in the different phases of clinical trials are- CAP 001, JR-141, TAK-609/SHP609/HGT-2310, GC1111 (Hunterase), DNL310, RGX-121, SB-913, AVR-RD-05, and others are expected to have a significant impact on the Hunter Syndrome market in the coming years.   
• In June 2022, In order to compare the effectiveness and safety of DNL310 vs. idursulfase in paediatric patients with neuronopathic or nonneuronopathic mucopolysaccharidosis Type II, Denali Therapeutics started a Phase II/III, multicenter, double-blind, randomised investigation.
• In February 2022, Newer, longer-term findings from a current Phase 1/2 clinical trial of DNL310 (ETV:IDS) are being presented at WORLDSymposiumTM, according to a statement from Denali Therapeutics Inc.
• In July 2021, Positive findings from a clinical trial evaluating the ETV: IDS, an experimental brain-penetrant enzyme replacement medication for the management of peripheral signs of Hunter syndrome, were released by Denali Therapeutics Inc. The findings will be made public at the 16
• In May 20221, A biopharmaceutical startup named Inventiva has confirmed that they will attend the Jefferies Virtual Healthcare Conference. The organisation is in charge of creating oral small molecule treatments for unmet medical needs in mucopolysaccharidoses (MPS) and other conditions. The company will discuss its corporate overview and hold investor meetings during this conference.
• In March 2021, To assess the safety, tolerability, and pharmacodynamics of RGX-121 in children 5 years of age and older with MPS II (Hunter Syndrome), Regenxbio started a Phase I/II multicenter, open-label trial. A functional copy of the iduronate-2-sulfatase (IDS) gene is to be delivered to the central nervous system using the gene therapy RGX121.

Hunter Syndrome Overview

Large sugar molecules known as glycosaminoglycans (also known as GAGs or mucopolysaccharides) accumulate in bodily tissues in the rare genetic illness known as Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II). A type of lysosomal storage disease, it.

Get a Free Sample PDF Report to know more about Hunter Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hunter-syndrome-pipeline-insight

Emerging Hunter Syndrome Drugs Under Different Phases of Clinical Development Include:

• CAP 001: Capsida Biotherapeutics
• JR-141: JCR Pharmaceuticals
• TAK-609/SHP609/HGT-2310: Takeda
• GC1111 (Hunterase): Green Cross Corporation/GC Pharma
• DNL310: Denali Therapeutics
• RGX-121: Regenxbio
• SB-913: Sangamo Therapeutics
• AVR-RD-05: AVROBIO

Hunter Syndrome Route of Administration

Hunter Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hunter Syndrome Molecule Type

Hunter Syndrome Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Hunter Syndrome Pipeline Therapeutics Assessment

• Hunter Syndrome Assessment by Product Type
• Hunter Syndrome By Stage and Product Type
• Hunter Syndrome Assessment by Route of Administration
• Hunter Syndrome By Stage and Route of Administration
• Hunter Syndrome Assessment by Molecule Type
• Hunter Syndrome by Stage and Molecule Type

DelveInsight’s Hunter Syndrome Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hunter Syndrome product details are provided in the report. Download the Hunter Syndrome pipeline report to learn more about the emerging Hunter Syndrome therapies

Some of the key companies in the Hunter Syndrome Therapeutics Market include:

Key companies developing therapies for Hunter Syndrome are – REGENXBIO Inc., Takeda Pharmaceutical Company Limited, Triley Bidco Limited (Clinigen Group PLC), JCR Pharmaceuticals, Sangamo Therapeutics, Denali Therapeutics Inc., Bioasis Technologies Inc., Inventiva, GC Pharma (Green Cross Holdings), Esteve, Avrobio Inc., CANbridge Life Sciences Ltd, and others.

Hunter Syndrome Pipeline Analysis:

The Hunter Syndrome pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Hunter Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hunter Syndrome Treatment.
• Hunter Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hunter Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hunter Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hunter Syndrome drugs and therapies

Hunter Syndrome Pipeline Market Drivers

• Increase in the number of the population suffering from hunter syndrome, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Hunter Syndrome Market.

Hunter Syndrome Pipeline Market Barriers

• However, high cost of treatment, heterogeneity of the disease, lack of awareness and other factors are creating obstacles in the Hunter Syndrome Market growth.

Scope of Hunter Syndrome Pipeline Drug Insight    

• Coverage: Global
• Key Hunter Syndrome Companies: Capsida Biotherapeutics, JCR Pharmaceuticals, Takeda, Green Cross Corporation/GC Pharma, Denali Therapeutics, Regenxbio, Sangamo Therapeutics, AVROBIO, and others
• Key Hunter Syndrome Therapies: CAP 001, JR-141, TAK-609/SHP609/HGT-2310, GC1111 (Hunterase), DNL310, RGX-121, SB-913, AVR-RD-05, and others
• Hunter Syndrome Therapeutic Assessment: Hunter Syndrome current marketed and Hunter Syndrome emerging therapies
• Hunter Syndrome Market Dynamics: Hunter Syndrome market drivers and Hunter Syndrome market barriers 

Request for Sample PDF Report for Hunter Syndrome Pipeline Assessment and clinical trials

Table of Contents 

1. Hunter Syndrome Report Introduction

2. Hunter Syndrome Executive Summary

3. Hunter Syndrome Overview

4. Hunter Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Hunter Syndrome Pipeline Therapeutics

6. Hunter Syndrome Late Stage Products (Phase II/III)

7. Hunter Syndrome Mid Stage Products (Phase II)

8. Hunter Syndrome Early Stage Products (Phase I)

9. Hunter Syndrome Preclinical Stage Products

10. Hunter Syndrome Therapeutics Assessment

11. Hunter Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hunter Syndrome Key Companies

14. Hunter Syndrome Key Products

15. Hunter Syndrome Unmet Needs

16 . Hunter Syndrome Market Drivers and Barriers

17. Hunter Syndrome Future Perspectives and Conclusion

18. Hunter Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services